Bendamustine-d4 (hydrochloride) |
رقم الكتالوجGC46914
One-Click Copy Product Info
|
A neuropeptide with diverse biological activities
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2802569-31-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Bendamustine-d4 is intended for use as an internal standard for the quantification of bendamustine by GC- or LC-MS. Bendamustine is a purine analog and DNA alkylating agent.1 It inhibits growth of SKW-3, Reh, CML-T1, BV-173, and HL-60 leukemia cell lines (IC50s = 27.0, 28.6, 15.6, 20.8, and 57.7 μM, respectively) but not MCF-7 and MDA-MB-231 breast cancer cell lines (IC50s = >200 μM for both).2 It is cytotoxic to patient-derived lymphocytic leukemia (B-CLL) cells (LD50s = 6.8-8.3 mg/ml).3 Bendamustine (50 mg/kg) inhibits tumor growth by 9 and 96% alone and in combination with ofatumumab, respectively, in a JVM-3 CLL mouse xenograft model.4 It activates the DNA-damage stress response, the base excision DNA repair pathway, and apoptosis, as well as inhibits mitotic checkpoints and induces mitotic catastrophe.1 Formulations containing bendamustine have been used to treat CLL and non-Hodgkin lymphoma.
1.Leoni, L.M., Bailey, B., Reifert, J., et al.Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agentsClin. Cancer Res.14(1)309-317(2008) 2.Konstantinov, S.M., Kostovski, A., Topashka-Ancheva, M., et al.Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell linesJ. Cancer Res. Clin. Oncol.128(5)271-278(2002) 3.SchwÄnen, C., Hecker, T., HÜbinger, G., et al.In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemiaLeukemia16(10)2096-2105(2002) 4.Haskova, Z., Whitacre, M.N., Dede, K.A., et al.Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemiaBr. J. Haematol.156(3)402-404(2012)
| Cas No. | 2802569-31-7 | SDF | |
| Canonical SMILES | ClCCN(C1=CC=C(N(C)C(CCCC(O)=O)=N2)C2=C1)C([2H])([2H])C([2H])([2H])Cl.Cl | ||
| Formula | C16H17Cl2D4N3O2.HCl | M.Wt | 398.8 |
| الذوبان | DMSO: Soluble,Methanol: Soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5075 mL | 12.5376 mL | 25.0752 mL |
| 5 mM | 501.5 μL | 2.5075 mL | 5.015 mL |
| 10 mM | 250.8 μL | 1.2538 mL | 2.5075 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)